Early Access

We are experts in the strategy, design, and implementation
of global early access and unlicensed medicines access programs

Early access programs

When patients have a life threatening or debilitating illness, their physicians have exhausted current treatment options or there simply aren’t any treatment options available or they are unable to enter a clinical trial, mechanisms exist across the globe to enable access to early access (pre-approval, managed access, compassionate use) or unlicensed medicines.

Healthcare professionals often seek to access these medicines for their patients and biopharmaceutical companies developing innovative medicines are increasingly making these medicines available to patients through early access and unlicensed medicines access programs.

 

WE HELP PATIENTS GET
ACCESS TO TREATMENT

WE RUN ACCESS PROGRAMS

CONSULTING SERVICES TO BIOTECH AND PHARMA

SUPPORTING HCPs

CONSULTING AND DELIVERY

The Inceptua Medicines Access management team pioneered many of the support services which are now standard across the industry, including:

At Inceptua we constantly strive to deliver value for our clients. We continually refine our offerings, based on client feedback, to ensure we maintain our position as the thought leader within this industry. Inceptua can support you whatever your need is, and we can create customized services to address your specific requirements.

If you are at the early stages of considering early access to one of your medicines, but aren’t quite ready to move ahead and engage with a vendor, then please take a look at our Ask Inceptua service, through which we commit to answering up to 10 questions you may have about pre-approval access, in a no-obligation setting.

If you would like to discuss how Inceptua can support you with pre-approval access to your medicines, please either call Inceptua on: +44 203 910 7670, or email at: access@inceptua.com

Our expert team have implemented over 200 access programs across all stages of the drug lifecycle, and supported healthcare professionals across the globe in accessing critical treatments for patients in need

We work with pharmaceutical and biotech companies of all sizes to design programs which meet global requirements.  As a team of leading experts in pre-approval and unlicensed access to medicines, we design strategies and programs to meet your objectives, the requirements for each specific product and the needs of the patients who are to be treated.

Our programs are powered by an understanding of specific need and delivered with compassion for patients. We understand the importance of your clinical development program, and ensure that any access program implemented delivers for both patients and physicians.

We have experience in the implementation of pre-approval access programs for medicines still in clinical development, as well as unlicensed medicines access programs providing access to medicines post first approval in countries where they are not commercially available.

Any questions?

Ask our experts

About

Mark has specialized in access programs for over 12 years and leads Medicines Access.

Mark Corbett

EXECUTIVE VICE PRESIDENT
MEDICINES ACCESS

About

With over 20 years of industry experience, Stuart leads the consulting arm of our Medicines Access team.

Stuart Bell

VICE PRESIDENT CONSULTING
MEDICINES ACCESS

About

With 20 years experience in the pharmaceutical industry, Ruth leads the implementation of our pre-approval access programs.

Ruth Rostron

VICE PRESIDENT PROJECT MANAGEMENT
MEDICINES ACCESS

About

Kelly has 25 experience in regulatory affairs and quality assurance, 10 of which specializing in Medicines Access regulations

Kelly Fearn

SENIOR DIRECTOR
HEAD OF REGULATORY

We are here to help
by providing vital advisory
and practical support for the
biopharmaceutical industry,
healthcare professionals, and
patient advocacy groups.

Early Access News and Insights

We use cookies to give you the best experience.